| Primary |
| Atrial Fibrillation |
28.9% |
| Thrombosis Prophylaxis |
26.3% |
| Cerebrovascular Accident Prophylaxis |
8.2% |
| Hypertension |
7.0% |
| Anticoagulant Therapy |
4.4% |
| Prophylaxis |
3.5% |
| Ischaemic Cardiomyopathy |
2.6% |
| Analgesic Therapy |
2.0% |
| Cardiac Failure |
2.0% |
| Coronary Artery Disease |
1.8% |
| Pain |
1.8% |
| Antibiotic Therapy |
1.5% |
| Cerebral Venous Thrombosis |
1.5% |
| Deep Vein Thrombosis |
1.5% |
| Antiinflammatory Therapy |
1.2% |
| Cardiac Failure Acute |
1.2% |
| Chronic Obstructive Pulmonary Disease |
1.2% |
| Gastritis Prophylaxis |
1.2% |
| Infection Prophylaxis |
1.2% |
| Postoperative Analgesia |
1.2% |
|
| Deep Vein Thrombosis |
20.4% |
| Pulmonary Embolism |
15.9% |
| Cerebral Infarction |
7.1% |
| Gastrointestinal Haemorrhage |
5.3% |
| Thrombosis |
5.3% |
| Renal Failure Acute |
4.4% |
| Cardiac Tamponade |
3.5% |
| Cerebrovascular Accident |
3.5% |
| Death |
3.5% |
| Haemorrhage |
3.5% |
| Rectal Haemorrhage |
3.5% |
| Atrial Thrombosis |
2.7% |
| Coagulopathy |
2.7% |
| Embolism |
2.7% |
| Embolism Arterial |
2.7% |
| Hypotension |
2.7% |
| Ischaemic Stroke |
2.7% |
| Malaise |
2.7% |
| Renal Failure |
2.7% |
| Upper Gastrointestinal Haemorrhage |
2.7% |
|
| Secondary |
| Product Used For Unknown Indication |
28.0% |
| Atrial Fibrillation |
22.9% |
| Hypertension |
8.5% |
| Drug Use For Unknown Indication |
6.6% |
| Cerebrovascular Accident Prophylaxis |
5.3% |
| Thrombosis Prophylaxis |
4.2% |
| Coronary Artery Disease |
3.8% |
| Anticoagulant Therapy |
3.0% |
| Prophylaxis |
2.5% |
| Pulmonary Embolism |
2.5% |
| Analgesic Therapy |
1.5% |
| Arthralgia |
1.5% |
| Diabetes Mellitus |
1.5% |
| Pain |
1.5% |
| Anxiety |
1.1% |
| Arrhythmia |
1.1% |
| Metastases To Lymph Nodes |
1.1% |
| Metastatic Neoplasm |
1.1% |
| Mineral Supplementation |
1.1% |
| Trousseau's Syndrome |
1.1% |
|
| Upper Gastrointestinal Haemorrhage |
13.5% |
| Deep Vein Thrombosis |
9.5% |
| Gastrointestinal Haemorrhage |
9.5% |
| Ultrasound Abdomen Abnormal |
8.1% |
| Melaena |
6.8% |
| Hypotension |
5.4% |
| Rectal Haemorrhage |
5.4% |
| Vomiting |
5.4% |
| Renal Failure Acute |
4.1% |
| Tachycardia |
4.1% |
| Thrombocytopenia |
4.1% |
| Activated Partial Thromboplastin Time Prolonged |
2.7% |
| Blood Urine |
2.7% |
| Cerebral Haemorrhage |
2.7% |
| Electrocardiogram Qrs Complex Prolonged |
2.7% |
| Epistaxis |
2.7% |
| Extrasystoles |
2.7% |
| Fall |
2.7% |
| Gingival Bleeding |
2.7% |
| Haematuria |
2.7% |
|
| Concomitant |
| Atrial Fibrillation |
23.9% |
| Product Used For Unknown Indication |
12.1% |
| Hypertension |
9.6% |
| Cardiac Failure |
7.5% |
| Cardiac Failure Chronic |
7.1% |
| Cerebral Artery Embolism |
5.0% |
| Diabetes Mellitus |
4.6% |
| Glaucoma |
4.3% |
| Depression |
3.6% |
| Pain |
3.6% |
| Embolic Stroke |
2.9% |
| Anticoagulant Therapy |
2.5% |
| Type 2 Diabetes Mellitus |
2.1% |
| Atrial Flutter |
1.8% |
| Constipation |
1.8% |
| Thrombosis Prophylaxis |
1.8% |
| Analgesic Therapy |
1.4% |
| Blood Pressure |
1.4% |
| Chronic Myeloid Leukaemia |
1.4% |
| Chronic Obstructive Pulmonary Disease |
1.4% |
|
| Atrial Fibrillation |
15.5% |
| Death |
8.6% |
| Dyspnoea |
6.9% |
| Impaired Driving Ability |
6.9% |
| Renal Failure Acute |
6.9% |
| Aspartate Aminotransferase Increased |
5.2% |
| Urinary Tract Infection |
5.2% |
| Alanine Aminotransferase Increased |
3.4% |
| Deafness |
3.4% |
| Hip Fracture |
3.4% |
| Hypoglycaemia |
3.4% |
| Infarction |
3.4% |
| Insomnia |
3.4% |
| Interstitial Lung Disease |
3.4% |
| Joint Swelling |
3.4% |
| Lethargy |
3.4% |
| Leukopenia |
3.4% |
| Oedema Peripheral |
3.4% |
| Psychomotor Hyperactivity |
3.4% |
| Renal Impairment |
3.4% |
|
| Interacting |
| Atrial Fibrillation |
36.2% |
| Diarrhoea |
12.8% |
| Product Used For Unknown Indication |
8.5% |
| Thoracic Vertebral Fracture |
8.5% |
| Constipation |
6.4% |
| Oesophageal Candidiasis |
6.4% |
| Anticoagulant Therapy |
4.3% |
| Cerebrovascular Accident |
4.3% |
| Antiandrogen Therapy |
2.1% |
| Cerebrovascular Accident Prophylaxis |
2.1% |
| Ischaemic Stroke |
2.1% |
| Mineral Supplementation |
2.1% |
| Pain |
2.1% |
| Prophylaxis |
2.1% |
|
| Drug Interaction |
14.3% |
| Petechiae |
10.7% |
| Upper Gastrointestinal Haemorrhage |
10.7% |
| Activated Partial Thromboplastin Time Prolonged |
7.1% |
| Gastrointestinal Haemorrhage |
7.1% |
| Haematuria |
7.1% |
| Acidosis |
3.6% |
| Cardiac Arrest |
3.6% |
| Cardiac Disorder |
3.6% |
| Haemorrhage |
3.6% |
| Immunosuppressant Drug Level Decreased |
3.6% |
| Overdose |
3.6% |
| Spontaneous Haematoma |
3.6% |
| Thrombin Time Prolonged |
3.6% |
| Thrombocytopenia |
3.6% |
| Thrombosis |
3.6% |
| Traumatic Haemorrhage |
3.6% |
| Urinary Retention |
3.6% |
|
